In twisting patent fight, CRISPR Therapeutics scores win in Europe … – BioPharma Dive
BioPharma Dive |
In twisting patent fight, CRISPR Therapeutics scores win in Europe …
BioPharma Dive … Harvard over similar claims in the U.S.; The EPO's decision is welcome news for CRISPR Therapeutics and ERS Genomics, two biotechs which license the hot … Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy Latest Stocks: The Analysts Set $27.00 Target Price for Crispr Therapeutics AG (CRSP) Crispr Therapeutics AG (CRSP) Now Covered by Analysts at Chardan Capital |
